Eli Lilly's GLP-1 and metabolic franchise can compound demand and cash flows while rate fears punish leveraged AI stories. It is preferable as a defensive-growth holding into its October 29 earnings over chasing a chip bounce. Continued healthcare volume leadership would support the sleeve; if semiconductors reclaim leadership first, the rotation is already crowded the other way. x.com  x.com 

Novo Nordisk could run with healthcare stocks as tech sells off, helped by the midterm health trend of the last 20 years. The market seems to be looking for value in health and pharma. Novo's $11.8 billion in free cash flow and major buybacks at these levels should eventually lift its depressed price once investors realize Novo and Eli Lilly can both do well in oral GLP-1s, where Novo leads. Novo might have found a bottom. x.com 

Eli Lilly is overvalued and needs to pull back, since a 40 P/E is high for any biotech or healthcare stock, which keeps Novo Nordisk the better side of the pair. A post the author replies to calls Novo an excellent entry today but doubts shorting Lilly given how much it has going on. x.com 

Managed-care insurance cash flows usually care less about AI bond yields than leveraged hyperscaler debt, making a managed-care sleeve preferable to chasing an AI bounce. UnitedHealth rose about 2.8% alongside Eli Lilly and Walmart after Deutsche Bank upgrades, while semiconductors weakened. x.com 

An early AI buildout, healthcare data, tokenized finance and copper's clearest supply-demand imbalance favor a 15-stock growth basket now. Marvell, Applied Optoelectronics, Nebius, Eli Lilly, Tempus, Ouster, Regal Rexnord, Bloom Energy, Fluence, SpaceX, Brazil's EWZ ETF, Nu Holdings, Coinbase, Securitize and the COPX copper-miners ETF are the picks. Keep Fluence smaller; SpaceX stays bullish long term despite rejecting $500B-$1T ARR in 2027. x.com 

UnitedHealth and healthcare look set to outperform through year-end, helped by midterm-year seasonality and defensive appeal. Over the last 20 years healthcare has generally done well from July through December in midterm election years. If the S&P 500 rolls into a bear market, UnitedHealth could outperform as investors rotate into defensive sectors. The bull case holds if medical cost ratios fall from AI and GLP-1 use and institutions rotate back into healthcare. x.com 

Healthcare's rotation from laggard to leader is not done, with the sector coming out of multiyear bases. It has been the most consistent sector in midterm election years for over 30 years, winning 80% of the time in the back half, and 22 healthcare companies beat the S&P 500 in 75%+ of midterms from 1994 to 2022. Focus names range from mature AbbVie, Lilly and UnitedHealth to large caps like Vertex and Amgen and riskier mid caps like Hims & Hers and Oscar Health. Start trimming from November. … Show more

Rotation out of extended semis, AI and tech infrastructure is structural oxygen for a broader bull market, not a bearish signal, as capital flows into software, healthcare, financials and payments. Favored names include Snowflake, Shopify, Datadog and Samsara in enterprise tech; Visa, Robinhood, Affirm, SoFi, Mastercard and American Express in finance; and UnitedHealth, Eli Lilly, Oscar Health, Hims & Hers and Moderna in healthcare. x.com 

Eli Lilly, Fortinet and Chewy are quality compounders growing on their own fundamentals, independent of the AI trade. Goldman Sachs says investors should favor companies with independent tailwinds, strong earnings growth and positive revisions. Lilly compounds through global adoption of its diabetes and obesity drugs, and analysts see estimates as too conservative. Fortinet's operating income beat forecasts by 22%. Chewy's low price already reflects the worst case, leaving significant upside. … Show more

Eli Lilly earns its place in a portfolio with a defensive profile plus tech-like growth rates, a strength that stands out on a down day for the market. An IBD MarketSurge chart accompanies the point. x.com